List of Excipients in Branded Drug TOPOSAR

Generic Drugs Containing TOPOSAR

Company	Ingredient	NDC	Excipient
Teva Parenteral Medicines Inc	etoposide	0703-5653	ALCOHOL
Teva Parenteral Medicines Inc	etoposide	0703-5653	ANHYDROUS CITRIC ACID
Teva Parenteral Medicines Inc	etoposide	0703-5653	POLYETHYLENE GLYCOL 300

What are the Most Frequently-Used Excipients in TOPOSAR?

# Of NDCs	Excipient
1	ALCOHOL
1	ANHYDROUS CITRIC ACID
1	POLYETHYLENE GLYCOL 300

TOPOSAR Excipient Strategy, Patent Position, and Commercial Opportunities

Last updated: August 4, 2026

TOPOSAR is an intravenous etoposide formulation used in oncology. Its commercial opportunity is not based on a new active ingredient or conventional composition patent. The strongest opportunities are differentiated injectable products that improve dilution stability, reduce excipient-related toxicity, simplify preparation, or support outpatient and pediatric use. The reference formulation uses a concentrated etoposide solution containing polyethylene glycol 400, polysorbate 80, ethanol, and citric acid.[1]

What is TOPOSAR and how is it formulated?

TOPOSAR is etoposide injection, USP, generally supplied at 20 mg/mL for intravenous administration. Etoposide is a topoisomerase II inhibitor used in regimens for small-cell lung cancer, testicular cancer, lymphomas, leukemias, and other malignancies.[1,2]

Attribute	TOPOSAR reference characteristics
Active ingredient	Etoposide
Dosage form	Sterile intravenous concentrate
Strength	20 mg/mL
Administration	Diluted intravenous infusion
Primary excipients	Polyethylene glycol 400, polysorbate 80, ethanol, citric acid
Therapeutic class	Antineoplastic topoisomerase II inhibitor
Regulatory pathway for standard generic	ANDA under section 505(j)
Novel formulation pathway	Potentially 505(b)(2)
Biosimilar exposure	None; etoposide is a small molecule
Core composition patent position	Legacy product with no meaningful new-molecule exclusivity

The formulation relies on cosolvent and surfactant technology because etoposide has limited aqueous solubility. The excipient system permits a concentrated injectable product but creates constraints involving precipitation, dilution, infusion compatibility, alcohol exposure, and hypersensitivity risk.

What excipients are used in TOPOSAR?

The key excipient strategy is a mixed-solvent system rather than a simple aqueous solution.

Polyethylene glycol 400

Polyethylene glycol 400 functions as a cosolvent. It supports etoposide solubilization in the concentrated vial and influences viscosity, dilution behavior, and tolerability.

Commercial implications include:

• Potentially high viscosity during preparation and transfer.
• Compatibility requirements with infusion containers and administration sets.
• A need to control water content and solvent ratios.
• Possible differentiation through lower PEG 400 loading.

A lower-PEG formulation could be commercially attractive if it maintains concentration and stability while reducing injection complexity. The technical challenge is preventing crystallization after dilution or during temperature excursions.

Polysorbate 80

Polysorbate 80 supports solubilization and helps maintain the drug in solution. It also introduces known formulation concerns, including peroxide formation, degradation products, extractables interaction, and hypersensitivity risk.

A next-generation formulation could target:

• Lower polysorbate 80 concentration.
• A different nonionic surfactant.
• A mixed-surfactant system.
• A surfactant-free nanoparticle or lipid-based delivery system.
• Improved control of oxidative impurities.

Any replacement must demonstrate equivalent or superior chemical stability, sterility, particulate control, infusion compatibility, and clinical tolerability.

Ethanol

Ethanol contributes to solubilization and allows the concentrated formulation to remain injectable after dilution. Its presence creates an identifiable product-positioning opportunity.

Relevant commercial concerns include:

• Pediatric exposure.
• Alcohol-sensitive patients.
• Drug interaction and institutional handling policies.
• Occupational exposure during compounding.
• Variation in ethanol exposure based on dose and infusion volume.

An ethanol-reduced or ethanol-free etoposide injection could command a premium in pediatric oncology, high-dose regimens, and institutions seeking to reduce solvent exposure. The product would likely require a formulation change supported by comparative pharmacokinetic, stability, and safety evidence.

Citric acid

Citric acid provides pH control and contributes to chemical stability. Changes to buffer type or concentration could affect solubility, degradation, container compatibility, and infusion tolerability.

A buffered formulation should not be evaluated only by initial pH. The relevant development package includes:

• pH after dilution.
• Long-term and accelerated stability.
• Freeze-thaw and temperature excursion behavior.
• Compatibility with saline and dextrose solutions.
• Particulate formation.
• Container closure interaction.

What formulation patents could protect a TOPOSAR successor?

A new formulation could receive patent protection if it contains a non-obvious composition or process that produces a measurable technical advantage. The legacy use of etoposide, basic solvent systems, and conventional infusion methods is unlikely to create a strong new patent position by itself.

Potential patentable claim categories

Claim category	Commercial value	Patent strength potential
Ethanol-free etoposide injection	High	Moderate to high if stability is unexpected
Reduced-polysorbate formulation	High	Moderate
PEG 400-free formulation	High	Moderate to high
Ready-to-use premixed infusion	High	Moderate
Concentration above conventional vial strength	Moderate	Moderate
Improved low-temperature stability	High	High if supported by comparative data
Anti-precipitation excipient system	High	High if technically distinctive
New container or administration system	Moderate	Moderate
Liposomal or nanoparticle etoposide	High but development-intensive	Potentially high
Manufacturing process reducing degradation	Moderate	Moderate

The strongest patent strategy would link composition claims to comparative performance. Examples include reduced precipitation after dilution, lower surfactant degradation, a longer refrigerated shelf life, or reduced alcohol exposure at equivalent dose.

Patent applicants should avoid relying solely on broad claims covering "etoposide with a pharmaceutically acceptable excipient." Such claims face substantial prior-art risk because etoposide injectable solvent systems have been described for decades.

How strong is the TOPOSAR patent estate?

TOPOSAR has a weak legacy-product patent profile relative to recently approved oncology products. Etoposide is an established small molecule, and the basic injectable formulation is commercially mature.

The principal barriers are regulatory and technical rather than composition-patent barriers:

1. Demonstrating pharmaceutical equivalence for an ANDA.
2. Matching or exceeding reference-product stability.
3. Controlling precipitation and particulate formation.
4. Establishing container and infusion compatibility.
5. Managing cytotoxic manufacturing controls.
6. Securing reliable sterile fill-finish capacity.

The public prescribing information identifies the product composition, dosage form, strength, preparation requirements, and safety information, but it is not a substitute for a current patent-family search or Orange Book review.[1] Based on the cited public materials, there is no basis to assign material value to a current TOPOSAR-specific composition patent estate.

What is the FDA regulatory status of TOPOSAR?

TOPOSAR is an FDA-regulated prescription injectable etoposide product. Standard generic competition generally proceeds through an ANDA when the proposed product matches the reference drug in active ingredient, dosage form, route, strength, and performance characteristics.[1,3]

ANDA opportunity

A conventional ANDA would focus on:

• Same active ingredient and injectable route.
• Pharmaceutical equivalence.
• Bioequivalence or applicable in vitro performance.
• Sterility and particulate requirements.
• Labeling consistent with the reference product.
• Demonstration of acceptable inactive ingredients and concentration.

For injectable products, the excipient composition may differ if the applicant satisfies FDA requirements and the differences do not create safety or efficacy concerns. The FDA Inactive Ingredient Database is relevant to excipient precedent, route, dosage form, and maximum potency considerations.[4]

505(b)(2) opportunity

A 505(b)(2) application may be more appropriate for:

• Ethanol-free etoposide.
• A ready-to-use infusion.
• A new concentration.
• A novel delivery vehicle.
• A depot, liposomal, or nanoparticle formulation.
• A materially different administration method.

The 505(b)(2) pathway can support product differentiation but usually requires a more substantial clinical and chemistry package than a standard ANDA.

When does TOPOSAR lose exclusivity, and what generic entry risks exist?

The active ingredient and conventional injectable formulation are legacy technologies. New-molecule exclusivity is not the principal commercial constraint. Generic entry risk is therefore high if a competitor can reproduce the required quality and stability profile at competitive cost.

Paragraph IV challenges

Paragraph IV certification is relevant only when an ANDA applicant challenges a listed patent in the Orange Book. A conventional etoposide injection product is unlikely to face a meaningful Paragraph IV barrier unless a sponsor has listed a later-issued formulation, method-of-use, or delivery patent.

The expected entry scenarios are:

Scenario	Likely impact
Standard ANDA with equivalent excipients	Rapid price competition
ANDA with different excipients	Moderate regulatory differentiation, limited pricing power
Ethanol-free 505(b)(2) product	Potential premium niche
Ready-to-use product	Institutional purchasing advantage
Shortage-related entrant	Temporary market share opportunity
Novel delivery formulation	Higher development cost and longer commercial runway

Method-of-use patents could affect specific oncology indications, dosing schedules, or combination regimens. They are less likely to block broad etoposide injection substitution if the generic label uses permitted carve-outs. Formulation patents would have greater commercial relevance if they cover a mandatory concentration, vehicle, or delivery system.

What formulation opportunities exist for TOPOSAR?

Ethanol-free injectable etoposide

This is the clearest excipient-led opportunity. The product could target pediatric oncology, alcohol-sensitive patients, and hospitals seeking to reduce solvent exposure.

The development objective would be a formulation with:

• Equivalent dose delivery.
• No ethanol or materially lower ethanol exposure.
• Lower or absent polysorbate 80.
• Stable vial storage.
• Reliable dilution in normal saline and dextrose.
• Low precipitation risk across clinically relevant concentrations.

Ready-to-use premixed infusion

A premixed bag could reduce pharmacy compounding steps and cytotoxic handling. It could also create a stronger hospital value proposition than a conventional vial.

Commercial advantages include:

• Lower preparation labor.
• Reduced dosing and dilution errors.
• Lower occupational exposure.
• Better suitability for centralized pharmacy operations.
• Potential use in outpatient infusion centers.

The main barriers are shelf-life, bag-material compatibility, adsorption, overfill controls, and transportation stability.

Low-surfactant or surfactant-free formulation

Reducing polysorbate 80 may improve tolerability and oxidative stability. A surfactant-free formulation could use alternative cosolvents, complexation, nanoparticles, or a prodrug approach.

This program has higher technical risk because the surfactant may be central to maintaining solubility. Strong patent protection would require evidence that the alternative system solves a recognized formulation problem.

Pediatric formulation

A pediatric-oriented product could focus on reduced alcohol, lower excipient burden, simplified dosing, and low-volume administration. Pediatric use may support premium positioning, although the market is smaller than the total adult oncology market.

Which companies could compete with a TOPOSAR formulation?

Competition is likely to come from generic injectable manufacturers, oncology-focused sterile manufacturers, contract development and manufacturing organizations, and suppliers with ready-to-use bag platforms.

Relevant competitive capabilities include:

• High-potency sterile manufacturing.
• Cytotoxic containment.
• Small-volume injectable fill-finish.
• Ready-to-use oncology bags.
• Lyophilization and reconstitution technology.
• Global regulatory infrastructure.
• Hospital contracting and group purchasing access.

The competitive threat is greater from a low-cost conventional generic than from a novel formulation. A differentiated product must therefore show a measurable pharmacy, safety, or administration benefit.

How does TOPOSAR compare with etoposide phosphate?

Etoposide phosphate is a water-soluble prodrug developed to address solubility and formulation limitations associated with etoposide. It is marketed in products such as Etopophos and may provide a different handling and reconstitution profile from conventional etoposide injection.[5]

Attribute	TOPOSAR	Etoposide phosphate
Active form	Etoposide	Etoposide phosphate prodrug
Formulation issue	Requires cosolvent system	Improved aqueous solubility
Excipient opportunity	Ethanol, PEG, surfactant reduction	Reconstitution and stability optimization
Regulatory strategy	ANDA or 505(b)(2) for differentiated product	Separate product-specific pathway
Commercial positioning	Lower-cost conventional or improved injection	Alternative formulation and handling profile
Patent risk	Primarily legacy and formulation-specific	Product- and formulation-specific

A new TOPOSAR successor would need to show why it is preferable to both conventional etoposide and etoposide phosphate. Convenience alone may not justify a premium unless it reduces pharmacy labor or clinically relevant solvent exposure.

What manufacturing and geographic IP barriers affect TOPOSAR?

The principal manufacturing barriers are sterile cytotoxic processing, containment, cleaning validation, operator protection, and supply-chain reliability. These barriers can limit competition even when patent protection is weak.

Geographic strategy should distinguish:

• United States ANDA or 505(b)(2) rights.
• European marketing authorization and centralized or national procedures.
• Japanese and Asian injectable requirements.
• Local manufacturing and tender rules.
• Patent term and supplementary protection certificate exposure.
• Country-specific data exclusivity.
• Hospital procurement preferences.

A U.S. formulation patent would not independently protect sales in Europe, China, India, or Latin America. Separate patent filings and regulatory approvals would be required. Process patents may provide practical protection where sterile manufacturing know-how is difficult to replicate, but they rarely prevent all alternative manufacturing routes.

What commercial opportunities exist for TOPOSAR?

The most attractive opportunities are:

1. Ethanol-free or low-ethanol injectable etoposide.
2. Ready-to-use premixed infusion bags.
3. Reduced-polysorbate formulations.
4. Pediatric low-excipient products.
5. Contract development of stable etoposide infusion systems.
6. Regional supply into markets with oncology injectable shortages.
7. Dual-source supply agreements with hospital systems.
8. Improved packaging and administration systems that reduce preparation waste.

Revenue exposure depends on the size of the etoposide injection market, generic price erosion, hospital contracting, and supply continuity. A conventional ANDA is likely to compete primarily on cost. A differentiated product can pursue higher gross margins, but only if it demonstrates a clear reduction in preparation time, solvent burden, waste, or adverse handling events.

Key Takeaways

• TOPOSAR is a legacy etoposide injectable formulation based on a cosolvent and surfactant system.
• The principal excipients are polyethylene glycol 400, polysorbate 80, ethanol, and citric acid.
• Core molecule and conventional formulation protection are weak compared with modern oncology products.
• The strongest opportunity is an ethanol-free, low-surfactant, or ready-to-use formulation.
• Standard generic entry is likely to be driven by ANDA competition rather than Paragraph IV litigation.
• A materially differentiated product may require a 505(b)(2) strategy.
• Patent value will depend on unexpected stability, precipitation, tolerability, or administration benefits.
• Sterile cytotoxic manufacturing and hospital supply execution are more important barriers than legacy composition patents.
• Etoposide phosphate is the principal formulation benchmark for a next-generation product.

FAQs About TOPOSAR Excipient and Patent Strategy

Is TOPOSAR an etoposide or etoposide phosphate product?

TOPOSAR is an etoposide injection product. Etoposide phosphate is a separate prodrug formulation with different solubility and formulation characteristics.

Can an ethanol-free TOPOSAR generic be filed as an ANDA?

It may be possible if the product satisfies applicable pharmaceutical equivalence, safety, performance, and inactive-ingredient requirements. A materially different formulation may instead require a 505(b)(2) application.

What is the main excipient risk in TOPOSAR?

The main risks involve ethanol exposure, polysorbate-related degradation or hypersensitivity, PEG-related viscosity, and precipitation after dilution.

Would a ready-to-use etoposide bag receive patent protection?

It could receive patent protection if the bag composition, concentration, container system, stability profile, or manufacturing process is novel and non-obvious. Packaging alone may provide limited protection.

Does TOPOSAR have biosimilar competition?

No. Etoposide is a chemically synthesized small molecule, so competition proceeds through generic drug pathways rather than biosimilar approval.

References

1. DailyMed. (n.d.). TOPOSAR- etoposide injection, solution. U.S. National Library of Medicine.
2. National Cancer Institute. (n.d.). Etoposide. National Institutes of Health.
3. U.S. Food and Drug Administration. (n.d.). Abbreviated new drug application (ANDA): Generics.
4. U.S. Food and Drug Administration. (n.d.). Inactive Ingredient Database.
5. DailyMed. (n.d.). Etopophos- etoposide phosphate injection. U.S. National Library of Medicine.